ALUMIS INC. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Alumis announced topline results from ONWARD3, a long-term extension study of envudeucitinib in moderate-to-severe plaque psoriasis. Of 773 patients receiving continuous treatment for up to 48 weeks, 54% achieved PASI 100 (complete skin clearance) and 75% achieved PASI 90; approximately 80–90% of patients who entered ONWARD3 already at PASI 90/100 sustained those responses. The company plans to submit an NDA to the FDA in Q4 2026; no new safety signals were observed. Separate integrated analysis across all ONWARD trials (890 patients) showed 47% PASI 100 and 66% PASI 90 at 48 weeks.
Why this rating
Phase 3 efficacy data are typically pivotal for late-stage biotech; a 54% PASI 100 is claimed best-in-class for oral therapies. NDA pathway clear and imminent. At ~$183M market cap, a successful approval could meaningfully expand revenue and valuation, though regulatory and commercialization risks remain substantial.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.